# Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension

> **NCT07713914** · PHASE4 · RECRUITING · sponsor: **University of Sao Paulo General Hospital** · enrollment: 196 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension (PAH)

## Interventions

- **DRUG:** Prostacyclin Pathway Agent
- **DRUG:** Sildenafil Dose Optimization

## Key facts

- **NCT ID:** NCT07713914
- **Lead sponsor:** University of Sao Paulo General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-22
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-12-31
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07713914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07713914, "Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07713914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*